Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Gastric Bypass | 11 | 2022 | 817 | 3.350 |
Why?
|
Bone Density | 35 | 2024 | 3533 | 3.060 |
Why?
|
Osteoporosis | 14 | 2023 | 1599 | 2.550 |
Why?
|
Obesity, Morbid | 7 | 2020 | 1277 | 1.690 |
Why?
|
Absorptiometry, Photon | 18 | 2023 | 1735 | 1.500 |
Why?
|
Bone Diseases, Metabolic | 5 | 2022 | 409 | 1.490 |
Why?
|
Bariatric Surgery | 6 | 2020 | 986 | 1.450 |
Why?
|
Gastroplasty | 3 | 2020 | 157 | 1.260 |
Why?
|
Fractures, Bone | 8 | 2024 | 2040 | 1.220 |
Why?
|
Bone Remodeling | 6 | 2018 | 579 | 1.120 |
Why?
|
Osteoporosis, Postmenopausal | 4 | 2021 | 393 | 1.050 |
Why?
|
Radius | 9 | 2023 | 440 | 1.010 |
Why?
|
Postmenopause | 9 | 2021 | 2509 | 0.960 |
Why?
|
Gastrectomy | 3 | 2021 | 670 | 0.940 |
Why?
|
Libido | 3 | 2020 | 119 | 0.910 |
Why?
|
Bone and Bones | 11 | 2023 | 2560 | 0.890 |
Why?
|
Osteonecrosis | 2 | 2022 | 229 | 0.800 |
Why?
|
Bone Density Conservation Agents | 6 | 2022 | 794 | 0.780 |
Why?
|
Goserelin | 3 | 2020 | 127 | 0.750 |
Why?
|
Teriparatide | 2 | 2014 | 227 | 0.710 |
Why?
|
Testosterone | 5 | 2020 | 2471 | 0.700 |
Why?
|
Adipose Tissue | 5 | 2021 | 3299 | 0.680 |
Why?
|
Histamine H2 Antagonists | 2 | 2011 | 165 | 0.630 |
Why?
|
Osteoporotic Fractures | 4 | 2024 | 408 | 0.580 |
Why?
|
Bone Resorption | 3 | 2018 | 720 | 0.570 |
Why?
|
Tibia | 8 | 2023 | 1065 | 0.570 |
Why?
|
Bone Marrow | 2 | 2016 | 2909 | 0.540 |
Why?
|
Body Composition | 9 | 2019 | 2416 | 0.530 |
Why?
|
Eunuchism | 1 | 2016 | 19 | 0.530 |
Why?
|
Bone Diseases | 1 | 2019 | 419 | 0.520 |
Why?
|
Insulin Resistance | 3 | 2020 | 3941 | 0.510 |
Why?
|
Subcutaneous Fat | 2 | 2017 | 393 | 0.500 |
Why?
|
Proton Pump Inhibitors | 2 | 2011 | 529 | 0.480 |
Why?
|
Intra-Abdominal Fat | 2 | 2017 | 608 | 0.440 |
Why?
|
Adiposity | 2 | 2020 | 1858 | 0.420 |
Why?
|
Ferric Compounds | 4 | 2020 | 377 | 0.420 |
Why?
|
Pelvic Bones | 3 | 2020 | 270 | 0.420 |
Why?
|
Parathyroid Hormone | 4 | 2016 | 1797 | 0.420 |
Why?
|
Tomography, X-Ray Computed | 10 | 2024 | 20500 | 0.410 |
Why?
|
Magnetics | 4 | 2021 | 600 | 0.410 |
Why?
|
Femur Neck | 3 | 2024 | 312 | 0.390 |
Why?
|
Obesity | 8 | 2023 | 12870 | 0.380 |
Why?
|
Magnetite Nanoparticles | 3 | 2018 | 315 | 0.370 |
Why?
|
Intestines | 1 | 2020 | 1906 | 0.370 |
Why?
|
Bone Morphogenetic Proteins | 2 | 2012 | 841 | 0.340 |
Why?
|
Energy Metabolism | 1 | 2020 | 2868 | 0.320 |
Why?
|
Middle Aged | 40 | 2024 | 219560 | 0.280 |
Why?
|
Pandemics | 4 | 2022 | 8611 | 0.280 |
Why?
|
Humans | 73 | 2024 | 758381 | 0.260 |
Why?
|
Diagnostic Imaging | 5 | 2020 | 3526 | 0.260 |
Why?
|
Body Mass Index | 4 | 2019 | 12876 | 0.250 |
Why?
|
Spine | 3 | 2018 | 1111 | 0.250 |
Why?
|
Delivery of Health Care | 3 | 2023 | 5331 | 0.240 |
Why?
|
Hip | 2 | 2017 | 251 | 0.240 |
Why?
|
Oxytocin | 2 | 2020 | 401 | 0.240 |
Why?
|
Estradiol | 4 | 2017 | 1933 | 0.230 |
Why?
|
Male | 39 | 2024 | 358742 | 0.230 |
Why?
|
Female | 45 | 2024 | 390316 | 0.230 |
Why?
|
Hip Fractures | 3 | 2018 | 987 | 0.220 |
Why?
|
Lumbar Vertebrae | 4 | 2022 | 1868 | 0.220 |
Why?
|
Medicare | 2 | 2019 | 6741 | 0.220 |
Why?
|
Propensity Score | 3 | 2020 | 1907 | 0.210 |
Why?
|
Cell Tracking | 2 | 2021 | 138 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3076 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3196 | 0.200 |
Why?
|
Peptide YY | 1 | 2022 | 136 | 0.200 |
Why?
|
Fanconi Syndrome | 1 | 2022 | 34 | 0.200 |
Why?
|
Hematopoietic Stem Cells | 1 | 2014 | 3384 | 0.190 |
Why?
|
Aging | 1 | 2020 | 8651 | 0.190 |
Why?
|
Practice Guidelines as Topic | 3 | 2013 | 7377 | 0.190 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2015 | 12076 | 0.190 |
Why?
|
Weight Loss | 3 | 2019 | 2671 | 0.180 |
Why?
|
Risk Assessment | 4 | 2024 | 23883 | 0.180 |
Why?
|
Adult | 29 | 2021 | 219916 | 0.180 |
Why?
|
Hypopituitarism | 2 | 2020 | 250 | 0.180 |
Why?
|
X-Ray Microtomography | 1 | 2022 | 443 | 0.180 |
Why?
|
Postoperative Complications | 2 | 2020 | 15638 | 0.180 |
Why?
|
Diabetes Insipidus, Neurogenic | 1 | 2020 | 20 | 0.180 |
Why?
|
Penile Erection | 1 | 2020 | 100 | 0.180 |
Why?
|
Anti-Mullerian Hormone | 1 | 2022 | 407 | 0.170 |
Why?
|
Gels | 1 | 2020 | 419 | 0.160 |
Why?
|
Muscle Strength | 2 | 2013 | 618 | 0.160 |
Why?
|
Body Fat Distribution | 1 | 2020 | 243 | 0.160 |
Why?
|
Anorexia Nervosa | 2 | 2019 | 1361 | 0.160 |
Why?
|
Injections, Subcutaneous | 1 | 2020 | 677 | 0.160 |
Why?
|
Aged | 20 | 2024 | 168217 | 0.160 |
Why?
|
Risk Factors | 12 | 2024 | 73806 | 0.160 |
Why?
|
Models, Animal | 2 | 2016 | 2112 | 0.160 |
Why?
|
Congresses as Topic | 2 | 2013 | 799 | 0.160 |
Why?
|
Vasopressins | 1 | 2020 | 354 | 0.160 |
Why?
|
Fractures, Spontaneous | 1 | 2020 | 231 | 0.160 |
Why?
|
Computer Simulation | 1 | 2012 | 6201 | 0.150 |
Why?
|
Administration, Cutaneous | 1 | 2020 | 712 | 0.150 |
Why?
|
Diphosphonates | 2 | 2022 | 636 | 0.150 |
Why?
|
Thrombophilia | 1 | 2020 | 304 | 0.140 |
Why?
|
Central Cord Syndrome | 1 | 2016 | 5 | 0.140 |
Why?
|
Unnecessary Procedures | 1 | 2020 | 411 | 0.140 |
Why?
|
Mass Screening | 1 | 2012 | 5425 | 0.130 |
Why?
|
Hyperthermia, Induced | 1 | 2020 | 416 | 0.130 |
Why?
|
Hydroxycholecalciferols | 1 | 2015 | 44 | 0.130 |
Why?
|
United States | 14 | 2024 | 72140 | 0.130 |
Why?
|
Galactose | 1 | 2017 | 296 | 0.130 |
Why?
|
Aerosols | 1 | 2018 | 631 | 0.130 |
Why?
|
Dextrans | 1 | 2017 | 573 | 0.120 |
Why?
|
Administration, Inhalation | 1 | 2018 | 1153 | 0.120 |
Why?
|
Anemia, Sickle Cell | 1 | 2023 | 1054 | 0.120 |
Why?
|
Societies, Medical | 3 | 2024 | 3891 | 0.120 |
Why?
|
Vitamin D Deficiency | 2 | 2021 | 1377 | 0.120 |
Why?
|
Contrast Media | 3 | 2018 | 5298 | 0.120 |
Why?
|
Treatment Outcome | 7 | 2020 | 64379 | 0.120 |
Why?
|
Algorithms | 3 | 2024 | 13959 | 0.120 |
Why?
|
Acromegaly | 1 | 2017 | 306 | 0.120 |
Why?
|
Cross-Sectional Studies | 6 | 2020 | 25953 | 0.110 |
Why?
|
Rare Diseases | 1 | 2019 | 619 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10747 | 0.110 |
Why?
|
Menopause | 1 | 2022 | 1639 | 0.110 |
Why?
|
Tibial Fractures | 1 | 2017 | 264 | 0.110 |
Why?
|
Porosity | 1 | 2014 | 349 | 0.110 |
Why?
|
Glycosylation | 1 | 2017 | 1095 | 0.110 |
Why?
|
Postprandial Period | 1 | 2015 | 314 | 0.110 |
Why?
|
Estrogen Replacement Therapy | 1 | 2020 | 1206 | 0.110 |
Why?
|
Home Care Services | 1 | 2020 | 647 | 0.110 |
Why?
|
Abdominal Fat | 1 | 2015 | 221 | 0.110 |
Why?
|
Continuity of Patient Care | 1 | 2020 | 1067 | 0.110 |
Why?
|
Case-Control Studies | 3 | 2015 | 22031 | 0.100 |
Why?
|
Health Resources | 1 | 2019 | 931 | 0.100 |
Why?
|
Hormones | 1 | 2016 | 869 | 0.100 |
Why?
|
Bed Rest | 1 | 2012 | 83 | 0.100 |
Why?
|
Patient Admission | 2 | 2019 | 1372 | 0.100 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4839 | 0.100 |
Why?
|
Vitamin D | 3 | 2021 | 3283 | 0.100 |
Why?
|
Radius Fractures | 1 | 2017 | 513 | 0.100 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1870 | 0.090 |
Why?
|
Mice, Inbred C57BL | 2 | 2022 | 22006 | 0.090 |
Why?
|
Procollagen | 1 | 2011 | 187 | 0.090 |
Why?
|
Phantoms, Imaging | 3 | 2019 | 2509 | 0.090 |
Why?
|
Longitudinal Studies | 4 | 2023 | 14481 | 0.090 |
Why?
|
Incidence | 3 | 2019 | 21273 | 0.090 |
Why?
|
Osteocalcin | 1 | 2011 | 274 | 0.090 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2016 | 498 | 0.090 |
Why?
|
Anti-Ulcer Agents | 1 | 2011 | 112 | 0.090 |
Why?
|
Young Adult | 10 | 2023 | 58808 | 0.090 |
Why?
|
Polysaccharides | 1 | 2017 | 1007 | 0.090 |
Why?
|
Recurrence | 2 | 2020 | 8426 | 0.090 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6293 | 0.090 |
Why?
|
Molecular Imaging | 1 | 2017 | 815 | 0.090 |
Why?
|
Estrogens | 1 | 2017 | 1520 | 0.090 |
Why?
|
Cell Count | 1 | 2014 | 1835 | 0.090 |
Why?
|
Advisory Committees | 2 | 2024 | 785 | 0.090 |
Why?
|
Animals | 9 | 2022 | 167777 | 0.090 |
Why?
|
Pharmaceutical Preparations | 1 | 2018 | 1090 | 0.090 |
Why?
|
Pilot Projects | 2 | 2020 | 8554 | 0.090 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2024 | 3432 | 0.080 |
Why?
|
Prospective Studies | 5 | 2022 | 54136 | 0.080 |
Why?
|
Follow-Up Studies | 5 | 2019 | 39060 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2022 | 1926 | 0.080 |
Why?
|
Disease Management | 1 | 2020 | 2500 | 0.080 |
Why?
|
Vision, Low | 1 | 2011 | 163 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6493 | 0.080 |
Why?
|
Calcium | 3 | 2012 | 5721 | 0.080 |
Why?
|
Nephritis | 1 | 2009 | 147 | 0.080 |
Why?
|
Dietary Supplements | 1 | 2021 | 3388 | 0.080 |
Why?
|
Time Factors | 4 | 2020 | 39873 | 0.080 |
Why?
|
Genetic Markers | 2 | 2012 | 2608 | 0.080 |
Why?
|
Fasting | 1 | 2014 | 1599 | 0.080 |
Why?
|
Cholesterol, HDL | 1 | 2015 | 1808 | 0.080 |
Why?
|
Neoplasms | 3 | 2023 | 22030 | 0.080 |
Why?
|
Neutrophils | 1 | 2021 | 3765 | 0.080 |
Why?
|
Collagen Type I | 1 | 2011 | 616 | 0.080 |
Why?
|
Hip Joint | 1 | 2014 | 1007 | 0.070 |
Why?
|
Calcinosis | 1 | 2016 | 1467 | 0.070 |
Why?
|
Choroidal Neovascularization | 1 | 2011 | 357 | 0.070 |
Why?
|
Body Weight | 2 | 2016 | 4603 | 0.070 |
Why?
|
Blindness | 1 | 2011 | 582 | 0.070 |
Why?
|
Boston | 1 | 2020 | 9304 | 0.070 |
Why?
|
Aged, 80 and over | 6 | 2020 | 58681 | 0.070 |
Why?
|
Cyclic AMP | 1 | 2010 | 1455 | 0.070 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2016 | 3758 | 0.070 |
Why?
|
Gastrointestinal Agents | 1 | 2011 | 508 | 0.070 |
Why?
|
Double-Blind Method | 1 | 2020 | 12262 | 0.060 |
Why?
|
Cholesterol | 1 | 2015 | 2901 | 0.060 |
Why?
|
Canada | 1 | 2011 | 2111 | 0.060 |
Why?
|
Premenopause | 2 | 2022 | 1038 | 0.060 |
Why?
|
Femur | 1 | 2012 | 1302 | 0.060 |
Why?
|
Proportional Hazards Models | 2 | 2017 | 12440 | 0.060 |
Why?
|
Cell Lineage | 1 | 2014 | 2533 | 0.060 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2012 | 1214 | 0.060 |
Why?
|
Immunoglobulin G | 1 | 2017 | 4540 | 0.060 |
Why?
|
Angiogenesis Inhibitors | 1 | 2015 | 2047 | 0.060 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2022 | 4562 | 0.060 |
Why?
|
Cohort Studies | 5 | 2021 | 41252 | 0.060 |
Why?
|
Spinal Fractures | 1 | 2011 | 702 | 0.060 |
Why?
|
Europe | 1 | 2011 | 3420 | 0.060 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2012 | 2895 | 0.060 |
Why?
|
Medication Adherence | 1 | 2016 | 2155 | 0.060 |
Why?
|
Macular Degeneration | 1 | 2011 | 1001 | 0.060 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3801 | 0.050 |
Why?
|
Mice | 5 | 2022 | 81107 | 0.050 |
Why?
|
Cardiovascular Diseases | 2 | 2019 | 15396 | 0.050 |
Why?
|
C-Reactive Protein | 1 | 2015 | 3812 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2016 | 4158 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3018 | 0.050 |
Why?
|
Mexican Americans | 1 | 2003 | 165 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2012 | 2215 | 0.050 |
Why?
|
Sickness Impact Profile | 1 | 2003 | 298 | 0.050 |
Why?
|
Atrial Fibrillation | 1 | 2020 | 5105 | 0.050 |
Why?
|
Aromatase Inhibitors | 2 | 2017 | 511 | 0.050 |
Why?
|
Tissue Distribution | 2 | 2016 | 2263 | 0.050 |
Why?
|
Tooth Extraction | 1 | 2022 | 229 | 0.050 |
Why?
|
Retrospective Studies | 6 | 2024 | 80170 | 0.050 |
Why?
|
Bicarbonates | 1 | 2022 | 292 | 0.050 |
Why?
|
B-Lymphocytes | 1 | 2014 | 4738 | 0.050 |
Why?
|
Multiple Sclerosis | 1 | 2016 | 3204 | 0.050 |
Why?
|
Patient Compliance | 1 | 2010 | 2685 | 0.040 |
Why?
|
Blood Glucose | 1 | 2014 | 6347 | 0.040 |
Why?
|
Alendronate | 1 | 2021 | 172 | 0.040 |
Why?
|
Emergency Service, Hospital | 2 | 2019 | 7810 | 0.040 |
Why?
|
Sex Factors | 2 | 2017 | 10505 | 0.040 |
Why?
|
Glioblastoma | 1 | 2015 | 3480 | 0.040 |
Why?
|
Vision, Ocular | 1 | 2003 | 454 | 0.040 |
Why?
|
Peptides | 1 | 2011 | 4341 | 0.040 |
Why?
|
Odds Ratio | 1 | 2011 | 9650 | 0.040 |
Why?
|
Peptide Fragments | 1 | 2011 | 5098 | 0.040 |
Why?
|
Insurance Claim Review | 2 | 2016 | 737 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2016 | 5818 | 0.040 |
Why?
|
Brain Neoplasms | 2 | 2020 | 8981 | 0.040 |
Why?
|
Durapatite | 1 | 2019 | 163 | 0.040 |
Why?
|
Coated Materials, Biocompatible | 1 | 2020 | 312 | 0.040 |
Why?
|
Age of Onset | 1 | 2024 | 3298 | 0.040 |
Why?
|
Cardiology Service, Hospital | 1 | 2019 | 239 | 0.040 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2009 | 2159 | 0.040 |
Why?
|
Four-Dimensional Computed Tomography | 1 | 2018 | 141 | 0.030 |
Why?
|
Perfusion Imaging | 1 | 2018 | 196 | 0.030 |
Why?
|
Spin Labels | 1 | 2018 | 336 | 0.030 |
Why?
|
Fertility Agents, Female | 1 | 2017 | 101 | 0.030 |
Why?
|
T-Lymphocytes | 1 | 2014 | 10171 | 0.030 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2017 | 132 | 0.030 |
Why?
|
Calcium, Dietary | 1 | 2019 | 529 | 0.030 |
Why?
|
Biomedical Technology | 1 | 2018 | 209 | 0.030 |
Why?
|
Amino Acids | 1 | 2022 | 1713 | 0.030 |
Why?
|
Laminectomy | 1 | 2016 | 224 | 0.030 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2017 | 275 | 0.030 |
Why?
|
Research Design | 1 | 2011 | 6154 | 0.030 |
Why?
|
Leuprolide | 1 | 2017 | 314 | 0.030 |
Why?
|
Rats, Inbred F344 | 1 | 2016 | 825 | 0.030 |
Why?
|
Carbocyanines | 1 | 2015 | 175 | 0.030 |
Why?
|
Adolescent | 5 | 2023 | 87888 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2011 | 9160 | 0.030 |
Why?
|
Metal Nanoparticles | 1 | 2018 | 396 | 0.030 |
Why?
|
Hydrodynamics | 1 | 2015 | 167 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2019 | 715 | 0.030 |
Why?
|
Psychometrics | 1 | 2003 | 3050 | 0.030 |
Why?
|
Optics and Photonics | 1 | 2015 | 304 | 0.030 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2015 | 695 | 0.030 |
Why?
|
Women's Health | 1 | 2022 | 2057 | 0.030 |
Why?
|
Angiography | 1 | 2018 | 1599 | 0.030 |
Why?
|
Head-Down Tilt | 1 | 2012 | 66 | 0.030 |
Why?
|
Microscopy, Phase-Contrast | 1 | 2012 | 110 | 0.030 |
Why?
|
Human Growth Hormone | 1 | 2017 | 638 | 0.030 |
Why?
|
Eating | 1 | 2019 | 1536 | 0.030 |
Why?
|
Postural Balance | 1 | 2016 | 617 | 0.020 |
Why?
|
Equipment Design | 1 | 2020 | 3507 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2016 | 1083 | 0.020 |
Why?
|
Finite Element Analysis | 1 | 2013 | 428 | 0.020 |
Why?
|
Phosphorus | 1 | 2012 | 335 | 0.020 |
Why?
|
Weight-Bearing | 1 | 2013 | 517 | 0.020 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2017 | 1153 | 0.020 |
Why?
|
Forecasting | 1 | 2020 | 2920 | 0.020 |
Why?
|
Cervical Vertebrae | 1 | 2016 | 977 | 0.020 |
Why?
|
Community Pharmacy Services | 1 | 2009 | 50 | 0.020 |
Why?
|
Databases, Factual | 2 | 2019 | 7980 | 0.020 |
Why?
|
Androgens | 1 | 2017 | 1291 | 0.020 |
Why?
|
Nanotechnology | 1 | 2015 | 707 | 0.020 |
Why?
|
Body Size | 1 | 2012 | 462 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2015 | 1188 | 0.020 |
Why?
|
Vaccination | 1 | 2021 | 3356 | 0.020 |
Why?
|
Accidental Falls | 1 | 2016 | 1056 | 0.020 |
Why?
|
Temperature | 1 | 2015 | 2219 | 0.020 |
Why?
|
Physical Fitness | 1 | 2012 | 732 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2012 | 2210 | 0.020 |
Why?
|
Medical Records Systems, Computerized | 1 | 2012 | 1190 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2021 | 3362 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2015 | 2058 | 0.020 |
Why?
|
Nanoparticles | 1 | 2016 | 1940 | 0.010 |
Why?
|
Administration, Oral | 1 | 2012 | 3993 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 2009 | 1673 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2018 | 14641 | 0.010 |
Why?
|
Los Angeles | 1 | 2003 | 243 | 0.010 |
Why?
|
Prevalence | 1 | 2019 | 15646 | 0.010 |
Why?
|
Visual Acuity | 1 | 2011 | 2642 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 12951 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18357 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2009 | 2768 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2015 | 8946 | 0.010 |
Why?
|
Insurance, Health | 1 | 2009 | 2495 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2020 | 11336 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2015 | 9273 | 0.010 |
Why?
|
Vision Disorders | 1 | 2003 | 1084 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2009 | 4217 | 0.010 |
Why?
|
Child | 1 | 2022 | 79813 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2003 | 2414 | 0.010 |
Why?
|
Language | 1 | 2003 | 1532 | 0.010 |
Why?
|
Hospitalization | 1 | 2009 | 10653 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 36285 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 2003 | 20052 | 0.000 |
Why?
|